Table 3.
Immune checkpoint inhibitors and CART in oncology and the reported clinical cardiotoxicity/cardiovascular events from 2011 to May 2017
| Generic/Trade Name | Approval Year | Category | Antigens | Disease Indications | Cardiotoxicity/Cardiovascular Events |
|---|---|---|---|---|---|
| Yervoy (Ipilimumab) | 2011 | ICI | CTLA‐4 | Metastatic melanoma | SR16,134‐136 |
| Opdivo (Nivolumab) | 2014, 2015, 2016 | ICI | PD‐1 | Metastatic melanoma, metastatic SNSCLC, ARCC | SR16,135‐140 |
| Keytruda (Pembrolizumab) | 2014, 2015, 2016 | ICI | PD‐1 | Head and neck SCC | SR16,135‐137,141‐143 |
| Tecentriq (Atezolizumab) | 2016 | ICI | PD‐L1 | Urothelial carcinoma and metastatic NSCLC | SR144 |
| Bavencio (avelumab) | 2017 | ICI | PD‐L1 | Merkel cell carcinoma | SR160, SR161, SR167 |
| Imfinzi (durvalumab) | 2017 | ICI | PD‐L1 | Advanced or metastatic urothelial carcinoma | SR162, SR167 |
| CART | Not yet | CART | CD19, MAGE‐A3 | Hematopoietic malignancies, melanoma | SR145‐159 |
Abbreviations: CTLA‐4 = Cytotoxic T‐lymphocyte‐associated antigen 4; ICIs = Immune checkpoint inhibitors; ARCC = Advanced renal cell carcinoma; CHL = Classical Hodgkin lymphoma; SNSCLC = Metastatic squamous non‐small cell lung cancer; SCC = Squamous cell carcinoma; NSCLC = Non‐small cell lung cancer; CART = Chimeric antigen receptor T cell therapy; SR = Supplemental references.